Why one of the biggest obstacles in brain cancer treatment is getting drugs to reach the tumor

TL;DR

• Many cancer drugs struggle to reach brain tumors, even if they work elsewhere in the body.
• The blood–brain barrier blocks most treatments from entering brain tissue.
• Many clinical trials now focus specifically on how drugs reach the tumor, not just how they work.

Why Drug Delivery Is Such a Major Challenge in Brain Cancer

One of the biggest challenges in treating brain cancer isn't just finding effective drugs — it's getting those drugs to actually reach the tumor.

Many treatments that work well for cancers elsewhere in the body struggle to reach brain tumors at all. Even highly promising therapies may fail simply because they cannot enter the brain in sufficient amounts to have an effect.

This means that treatment success in brain cancer is often limited not by the drug itself, but by whether it can physically access the tumor.

How the Blood–Brain Barrier Blocks Treatment

The brain is protected by a tightly regulated system called the blood–brain barrier. Its role is to shield the brain from harmful substances circulating in the bloodstream.

This barrier is made up of specialized blood vessels and support cells that carefully control what can pass into brain tissue. While this protection is essential for brain health, it also blocks many cancer drugs — including chemotherapy, targeted therapies, and some immune-based treatments.

As a result, some medications never reach the tumor in high enough concentrations to be effective. Treatments that would otherwise work may appear ineffective simply because they cannot cross this barrier. The National Cancer Institute explains this challenge in more detail in its overview of brain tumors and treatment limitations.

How Researchers Are Working to Overcome This Obstacle

Because the blood–brain barrier is such a significant hurdle, researchers are developing new strategies focused specifically on drug delivery.

These approaches include designing drugs that can cross the barrier more easily, using targeted delivery systems that carry treatments directly to tumor cells, and testing methods that temporarily open the barrier in controlled ways. Each strategy aims to increase drug access to the tumor while still protecting healthy brain tissue.

Balancing safety and effectiveness is critical. Opening the barrier too much can risk damage to normal brain cells, while leaving it intact can prevent treatment from working at all. This balance is a central focus of modern brain cancer research, including work highlighted in Nature Reviews Cancer on drug delivery across the blood–brain barrier.

Why Drug Delivery Shapes Clinical Trials — and How PACT AI Helps

Because getting drugs to the tumor is such a fundamental challenge, many brain cancer clinical trials are designed around delivery strategies, not just the drug itself.

Some trials test therapies engineered to cross the blood–brain barrier, while others focus on novel delivery methods or timing treatments around temporary changes in barrier permeability.

PACT AI helps patients and caregivers identify clinical trials built around these delivery approaches, making it easier to explore options designed for the unique barriers of brain cancer treatment — not just the tumor, but the path to reaching it.

Learn more about how PACT AI can help →

Have questions? Reach out at contact@pact-ai.com.